Cardiac allograft vasculopathy in heart transplant recipients from hepatitis C viremic donors

CONCLUSION: Our data show that NAT+ donors conferred no increased risk for early CAV or subclinical IVUS disease following transplantation in a cohort of heart transplant patients who were treated for HCV, suggesting the short-term safety of this strategy to maximize the pool of available donor hearts.PMID:38545881 | DOI:10.1111/ctr.15294

Source: Atherosclerosis - March 28, 2024 Category: Cardiology Authors: Bernard S Kadosh Antoinette S Birs Erin Flattery Maxine Stachel Kimberly N Hong Yuhe Xia Claudia Gidea Saima Aslam Louai Razzouk Tajinderpal Saraon Randal Goldberg Shaline Rao Victor Pretorius Nader Moazami Deane E Smith Eric D Adler Alex Reyentovich Source Type: research